How to Respond to an FDA 483 (and Warning Letter) in 15 Working Days
From The GMP Insider · 15:07
Show by Tushar Arora
The inspection is over — and the second half of it has just started. Your written response to a Form FDA 483 is due within 15 working days, and FDA weighs it before deciding whether the matter ends there or escalates to a Warning Letter. Marcus and Priya lay out the full 15-day playbook: what a 483 is and is not, day-one triage and ownership, extent-of-condition review, root cause and CAPA discipline, evidence and timelines, the cold-read challenge review, and the five failures that sink responses again and again.• What a Form FDA 483 is — and is not: inspectional observations, not a final agency determination• The 15-working-day clock: when it starts, and why a late response can arrive after the decision• Days 1–2: one response owner, every observation logged verbatim, containment and extent-of-condition• Days 3–7: real root cause, and separating correction, corrective action, preventive action, and effectiveness checks• Days 8–15: how to structure and write the response, tone, disagreement with evidence, and the cold-read review• Warning Letters: same discipline, higher stakes — responding to the pattern, not just the paragraphs• The five failures that sink responses: narrow fixes, human-error shortcuts, promise piles, defensive tone, missed commitmentsNew episodes every Monday and Wednesday — follow The GMP Insider so you never miss one.Connect with Tushar Arora on LinkedIn: https://www.linkedin.com/in/tushar-a-926382161Watch on YouTube: https://www.youtube.com/@TheGMPInsiderProduced with AI assistance.
More episodes of The GMP Insider
More episodes
- Environmental Monitoring: Alert vs Action Limits & Trending
- ICH Q9(R1) Quality Risk Management: What's Actually New
- Change Control Management: What Gets Companies in Trouble
- Contamination Control Strategy (CCS) Under EU GMP Annex 1
- Deviation Investigation & Root Cause Analysis: 5 Whys Done Right
- FDA Inspection Readiness 2026: The New Cross-System Inspection Model
- Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained
- Why FDA Rejects Your CAPA: 5 CAPA Effectiveness Failures Explained
- OOS Investigation Explained: Phase 1 vs Phase 2 (21 CFR 211.192)
- ALCOA+ Explained: The 9 Data Integrity Principles FDA Actually Cites
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.